Xiaoyan Yin1, Subha Subramanian1, Christine M Willinger1, George Chen1, Peter Juhasz1, Paul Courchesne1, Brian H Chen1, Xiaohang Li1, Shih-Jen Hwang1, Caroline S Fox1, Christopher J O'Donnell1, Pieter Muntendam1, Valentin Fuster1, Ivana Bobeldijk-Pastorova1, Silvia C Sookoian1, Carlos J Pirola1, Neal Gordon1, Aram Adourian1, Martin G Larson1, Daniel Levy1. 1. Framingham Heart Study (X.Y., S.S., C.M.W., G.C., P.C., B.H.C., S.-J.H., C.S.F., C.J.O., M.G.L., D.L.), Framingham, Massachusetts 01702; Boston University Department of Mathematics and School of Public Health (X.Y., M.G.L.), Boston, Massachusetts 02118; Population Sciences Branch (S.S., C.M.W., G.C., P.C., B.H.C., S.-J.H., C.S.F., C.J.O., D.L.), Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892; BG Medicine, Inc (P.J., X.L., P.M., N.G., A.A.), Waltham, Massachusetts 02451; Department of Medicine (C.S.F.), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115; Department of Medicine (C.J.O.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114; Mount Sinai School of Medicine (V.F.), New York, New York 10029; Centro Nacional de Investigaciones Cardiovasculares (V.F.), 28029 Madrid, Spain; TNO Triskelion BV, Inc (I.B.-P.), 3704 HE Zeist, The Netherlands; Institute of Medical Research A Lanari-IDIM, University of Buenos Aires (S.C.S., C.J.P.), National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C11428, Argentina; and Boston University School of Medicine (D.L.), Boston, Massachusetts 02118.
Abstract
CONTEXT: Metabolic dysregulation underlies key metabolic risk factors—obesity, dyslipidemia, and dysglycemia. OBJECTIVE: To uncover mechanistic links between metabolomic dysregulation and metabolic risk by testing metabolite associations with risk factors cross-sectionally and with risk factor changes over time. DESIGN: Cross-sectional—discovery samples (n = 650; age, 36–69 years) from the Framingham Heart Study (FHS) and replication samples (n = 670; age, 61–76 years) from the BioImage Study, both following a factorial design sampled from high vs low strata of body mass index, lipids, and glucose. Longitudinal—FHS participants (n = 554) with 5–7 years of follow-up for risk factor changes. SETTING: Observational studies. PARTICIPANTS: Cross-sectional samples with or without obesity, dysglycemia, and dyslipidemia, excluding prevalent cardiovascular disease and diabetes or dyslipidemia treatment. Age- and sex-matched by group. INTERVENTIONS: None. MAIN OUTCOME MEASURE(S): Gas chromatography-mass spectrometry detected 119 plasma metabolites. Cross-sectional associations with obesity, dyslipidemia, and dysglycemia were tested in discovery, with external replication of 37 metabolites. Single- and multi-metabolite markers were tested for association with longitudinal changes in risk factors. RESULTS: Cross-sectional metabolite associations were identified with obesity (n = 26), dyslipidemia (n = 21), and dysglycemia (n = 11) in discovery. Glutamic acid, lactic acid, and sitosterol associated with all three risk factors in meta-analysis (P < 4.5 × 10−4). Metabolites associated with longitudinal risk factor changes were enriched for bioactive lipids. Multi-metabolite panels explained 2.5–15.3% of longitudinal changes in metabolic traits. CONCLUSIONS: Cross-sectional results implicated dysregulated glutamate cycling and amino acid metabolism in metabolic risk. Certain bioactive lipids were associated with risk factors cross-sectionally and over time, suggesting their upstream role in risk factor progression. Functional studies are needed to validate findings and facilitate translation into treatments or preventive measures.
CONTEXT: Metabolic dysregulation underlies key metabolic risk factors—obesity, dyslipidemia, and dysglycemia. OBJECTIVE: To uncover mechanistic links between metabolomic dysregulation and metabolic risk by testing metabolite associations with risk factors cross-sectionally and with risk factor changes over time. DESIGN: Cross-sectional—discovery samples (n = 650; age, 36–69 years) from the Framingham Heart Study (FHS) and replication samples (n = 670; age, 61–76 years) from the BioImage Study, both following a factorial design sampled from high vs low strata of body mass index, lipids, and glucose. Longitudinal—FHS participants (n = 554) with 5–7 years of follow-up for risk factor changes. SETTING: Observational studies. PARTICIPANTS: Cross-sectional samples with or without obesity, dysglycemia, and dyslipidemia, excluding prevalent cardiovascular disease and diabetes or dyslipidemia treatment. Age- and sex-matched by group. INTERVENTIONS: None. MAIN OUTCOME MEASURE(S): Gas chromatography-mass spectrometry detected 119 plasma metabolites. Cross-sectional associations with obesity, dyslipidemia, and dysglycemia were tested in discovery, with external replication of 37 metabolites. Single- and multi-metabolite markers were tested for association with longitudinal changes in risk factors. RESULTS: Cross-sectional metabolite associations were identified with obesity (n = 26), dyslipidemia (n = 21), and dysglycemia (n = 11) in discovery. Glutamic acid, lactic acid, and sitosterol associated with all three risk factors in meta-analysis (P < 4.5 × 10−4). Metabolites associated with longitudinal risk factor changes were enriched for bioactive lipids. Multi-metabolite panels explained 2.5–15.3% of longitudinal changes in metabolic traits. CONCLUSIONS: Cross-sectional results implicated dysregulated glutamate cycling and amino acid metabolism in metabolic risk. Certain bioactive lipids were associated with risk factors cross-sectionally and over time, suggesting their upstream role in risk factor progression. Functional studies are needed to validate findings and facilitate translation into treatments or preventive measures.
Authors: Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy Journal: Am J Epidemiol Date: 2007-03-19 Impact factor: 4.897
Authors: Wolfram Goessling; Joseph M Massaro; Ramachandran S Vasan; Ralph B D'Agostino; R Curtis Ellison; Caroline S Fox Journal: Gastroenterology Date: 2008-09-20 Impact factor: 22.682
Authors: Ele Ferrannini; Andrea Natali; Stefania Camastra; Monica Nannipieri; Andrea Mari; Klaus-Peter Adam; Michael V Milburn; Gabi Kastenmüller; Jerzy Adamski; Tiinamaija Tuomi; Valeriya Lyssenko; Leif Groop; Walter E Gall Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461
Authors: Terry E Jones; Walter J Pories; Joseph A Houmard; Charles J Tanner; Donghai Zheng; Kai Zou; Paul M Coen; Bret H Goodpaster; William E Kraus; G Lynis Dohm Journal: Surgery Date: 2019-06-25 Impact factor: 3.982
Authors: Charlotte Andersson; Andrew D Johnson; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan Journal: Nat Rev Cardiol Date: 2019-11 Impact factor: 32.419